<DOC>
	<DOCNO>NCT03054792</DOCNO>
	<brief_summary>This study test feasibility use novel/existing image technology focus hypoxia measurement determine `` response therapy '' pediatric soft tissue sarcoma pilot study . Specifically , investigator compare sensitivity Blood Oxygen Level Dependent [ BOLD ] , Diffusion-Weighted [ DW ] MRI , Magnetic Resonance Spectroscopy ( MRS ) 18F-FAZA PET-MRI conventional MRI detect measurement change start completion neoadjuvant therapy ( `` response therapy '' ) child adolescent ( 7-18 year ) suspicion sarcoma tumor . Clinicians scientist may use result propose hypoxia-imaging surrogate marker adjust/modify therapeutic scheme patient personalized basis .</brief_summary>
	<brief_title>Molecular-Functional Imaging Hypoxia Childhood Sarcomas</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<criteria>Referred confirm suspected sarcoma tumor ( rhabdomyosarcoma [ RMS ] nonrhabdomyomatous sarcoma ) present extraosseous component ; Candidate neoadjuvant therapy consist standard systemic chemotherapy without radiation therapy Patients general contraindication MRI scan ( metal foreign body , pacemaker , inability tolerate examination without sedation ) ; Patients know immunodeficiency/sickle cell disease/collagen vascular disease/another malignancy ; Patients clinical indication neoadjuvant therapy prior surgery ; Patients chronic pulmonary disease ; Patients diagnosis confirm initial suspicion RMS nonRMS .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>